GlobeNewswire by notified

Fobi Signs Agreement With Empower Clinics To Fully Integrate Empower Clinic’s Kai Care Client Testing Data Base

Share

Empower To Leverage Fobi’s Wallet Pass Technology To Provide Verified Credentials For Secure Real Time Digital Health Care Notifications, Scheduling, Education And Client Messaging to All Kai Care Clients

VANCOUVER, British Columbia, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Fobi AI Inc. Inc. (FOBI:TSXV FOBIF:OTCQB) (the “Company” or “Fobi”), a leader in providing real-time data analytics through artificial intelligence to drive customer activation and engagement, is pleased to announce the Company has entered into a Service Agreement with Empower Clinics Inc. (CBDT:CSE) ("Empower") to integrate Fobi’s artificial Intelligence data applications and wallet pass platform into Empower’s Kai Care COVID-19 Testing product.  

Fobi Agreement Supports Empower’s Goal of Becoming A Cutting Edge Health Care Provider and Innovator. 

The Service agreement involves the integration of Fobi’s Wallet pass platform into the Kai Care COVID-19 testing product and back-end lab management system, which will create a much more secure and seamless next level of digital customer experience for not only COVID-19 tests, receiving results and providing verification of a negative Covid test, but for all other future testing applications as well.  As part of the Kai Care testing process, all customers will now have the ability to download a Kai Care Wallet pass directly into the native wallet that lives in all Apple & Android mobile phones. The Kai Care Pass will then be used for delivering test results direct to the mobile wallet in a safe and secure format. The new digital offering is very well timed given various international government mandates in regards to digital health passport requirements with proof of vaccinations and negative Covid test requirements. 

Empower To Leverage Fobi Ai Artificial Intelligence To Deliver Kai Care Clients Personalized Client Experience Which Provides Untapped And Potential New Line Revenue Opportunities. 

The Kai Care Wallet pass can also be used by Empower as a new customer engagement channel.  User adoption and retention of Wallet passes is much higher than normal mobile phone Apps, and campaigns for additional Kai Labs tests or relevant 3rd party products or services can be pushed out to their customers through banner ads on the front of the Wallet pass, links on the back of the Wallet pass, or through push notifications to customer mobile phone lock screens.  The new integrated solution also has a very high level of data security, with Fobi’s Wallet pass powered by Hedera Hashgraph. This new engagement channel also opens up potentially new advertising and data monetization options for both Empower and Fobi. In particular, Empower can now use the Wallet pass to promote and monetize products such as their own new testing products, as well as other 3rd party products such as travel insurance, etc.  Under the terms of the agreement, Fobi will receive revenue for each Wallet pass downloaded and Fobi and Empower will split the proceeds of any new advertising or data monetization revenue opportunities realized from this service agreement.  

Empower CEO Steven McAuley stated: “Testing and vaccinations are becoming a pillar of everyday life as society continues its fight against COVID-19. I’m proud to deepen our relationship with Fobi and meet the massive demand for reliable, secure and easy COVID-19 testing results and verification sharing. By working together our companies are supporting a safe reopening for individuals, businesses, schools, and so much more.”

This service agreement builds upon the relationship between Fobi (previously Loop Insights) and Empower that was announced in October 2020.  Since then, Empower Clinics have released their own E-Commerce site and signed major distribution deals with several pharmacies and retail outlets across North America to stock Kai Care testing kits on their shelves.  Empower are expecting additional distribution deals to be signed in the near future, which will increase the number of kits sold and customers worldwide, which management believes bodes well for revenue projections for both Empower and Fobi.  

A recent report from Grandview Research shows the COVID-19 Antigen Testing Market size will grow at a CAGR of 6.7% from 2021 and will reach USD $8.3 Billion by 2027.  With Fobi’s Wallet pass platform enabling an even more secure and seamless customer experience for Covid testing and result verification, it is anticipated that Empower will increase their share of that market significantly.

Fobi CEO Rob Anson stated: “Powering the Kai Care Wallet pass and supporting Empower to leverage our artificial intelligence data applications clearly provides Empower Clinics and Kai Care with a clear product differentiator in the testing marketplace. There are other testing providers out there, but none of which offer real time results delivered directly to the wallet. The Kai Care Wallet pass solution will provide the means to deliver a new level of personalized client engagement, scheduling and messaging. This new product release also provides Empower and Fobi with the ability to generate additional revenue through the data and advertising monetization opportunities. We are very excited to continue our support of our strong partnership with Empower Clinics.”

This Press Release Is Available on the Fobi Website, the Empower Website, as well as the FOBI Verified Forum On AGORACOM For Shareholder Discussion And Management Engagement.

About Empower

Empower is an integrated healthcare company that provides body and mind wellness for patients through its clinics, with digital and telemedicine care, and world-class medical diagnostics laboratories. Supported by an experienced leadership team, Empower is aggressively growing its clinical and digital presence across North America. Our Health & Wellness and Diagnostics & Technology business units are positioned to positively impact the integrated health of our patients, while simultaneously providing long term value for our shareholders.

CONTACTS:
Investors:
Steven McAuley CEO
s.mcauley@empowerclinics.com 604-789-2146

Investors:
Tamara Mason
Business Development & Communications
t.mason@empowerclinics.com
416-671-5617

About Fobi

Fobi is a cutting-edge data intelligence company that helps our clients turn real-time data into actionable insights and personalized customer engagement to generate increased profits. Fobi’s unique IoT device has the ability to integrate seamlessly into existing infrastructure to enable data connectivity across online and on-premise platforms creating highly scalable solutions for our global clients. Fobi partners with some of the largest companies in the world to deliver best-in-class solutions and operates globally in the retail, telecom, sports & entertainment, casino gaming, and hospitality & tourism industries.

For more information, please contact:

Fobi AI Inc.Fobi Website: www.fobi.ai
Rob Anson, CEOFacebook: @ Fobiinc
T : +1 877-754-5336 Ext. 3Twitter: @ Fobi_inc
E: ir@fobi.aiLinkedIn: @ Fobiinc

This news release contains certain statements that constitute forward-looking statements or information, including statements regarding Fobi's business and technology; the ability of Fobi to engage with industry participants to achieve its goals; the development of Fobi's technology; and the viability of Fobi's business model. Such forward-looking statements are subject to numerous risks and uncertainties, some of which are beyond Fobi's control, including the impact of general economic conditions, industry conditions, competition from other industry participants, stock market volatility, and the ability to access sufficient capital from internal and external sources. Although Fobi believes that the expectations in its forward-looking statements are reasonable, they are based on factors and assumptions concerning future events which may prove to be inaccurate. Those factors and assumptions are based upon currently available information. Such forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that could influence actual results or events and cause actual results or events to differ materially from those stated, anticipated, or implied in the forward-looking statements. As such, readers are cautioned not to place undue reliance on the forward-looking statements, as no assurance can be provided as to future results, levels of activity, or achievements. The forward-looking statements contained in this news release are made as of the date of this news release and, except as required by applicable law, Fobi does not undertake any obligation to publicly update or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise. The forward-looking statements contained in this document are expressly qualified by this cautionary statement. Trading in the securities of Fobi should be considered highly speculative. There can be no assurance that Fobi will be able to achieve all or any of its proposed objectives.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this release.

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

McWhorter Foundation Preparing Legal Battle Against J.P. Morgan Over IPO Discrimination and LBO Biases28.3.2024 19:28:47 CET | Press release

PALM BEACH, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- McWhorter Foundation is poised to launch a groundbreaking legal battle against financial giant J.P. Morgan. With a focus on challenging discriminatory practices in leveraged buyouts (LBOs) and initial public offerings (IPOs), The McWhorter Foundation aims to break down barriers and advocate for equal access to capital markets. Exposing Inequities in IPOs: Recent analyses have highlighted disparities in IPO access, with minority-owned businesses facing systemic hurdles in accessing public markets. McWhorter's legal challenge will illuminate these inequities, compelling J.P. Morgan to address its role in perpetuating barriers to entry for underrepresented entrepreneurs. Leveraging Data for Change: Backed by comprehensive data and extensive research, McWhorter's legal team will present compelling evidence of discrimination in J.P. Morgan's IPO practices. By highlighting patterns of exclusion and unequal treatment, McWhorter Foundation s

Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC28.3.2024 19:00:00 CET | Press release

Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Leuven, BELGIUM – March 28, 2024 – 07:00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received transparency notifications as follows: Oxurion received a transparency notification on March 27, 2024, from Atlas Special Opportunities, LLC indicating that as of March 19, 2024, it held 0 (zero) shares of the then outstanding 5,753,951,723 shares, and therefore crossed below the threshold (3%) by virtue of the sale of voting securities. See Annex 1. About Oxurion Oxurion (Euronext Brussels: OXUR) is engaged in developing next-generation standard of care ophthalmic therapies for the treatment of retinal disease. Oxurion is based in Leuven, Belgium. More information is available at www.oxurion.com. Important information about forward-looking statements Certain statements in this press rele

C.K. McWhorter: Running to a Solution Of Equality and Sustainability28.3.2024 18:48:29 CET | Press release

MIAMI, March 28, 2024 (GLOBE NEWSWIRE) -- In a groundbreaking endeavor, C.K. McWhorter, renowned for his pioneering spirit in luxury and finance, is embarking on a transformative journey to reshape the narrative of desirability. By harnessing the allure of luxury, McWhorter aims to catalyze a paradigm shift towards equality and sustainability, ensuring that these principles become the most coveted and revered ideals worldwide. With a profound understanding of the power of influence, McWhorter recognizes that luxury sets the standard for aspiration and desire. Leveraging this influence, he seeks to redefine what it means to truly desire and value, shifting the focus from just material possessions to ethical principles that benefit humanity and the planet. "Luxury has long been synonymous with opulence and exclusivity, but it's time for us to redefine its meaning," says McWhorter. "True luxury is in equality and sustainability – in knowing that our desires are aligned with values that up

Multitude Group Annual Report 2023 published - on track for substantial profitable growth in 2024 and beyond28.3.2024 18:30:00 CET | Press release

Multitude Group Annual Report 2023 published - on track for substantial profitable growth in 2024 and beyond Guidance for 2023 achieved: EBIT plus 44.8% to EUR 45.6 million Revenue up 8.5 % to EUR 230.5 millionNet profit jumped to EUR 16.4 million, basic earnings per share amount to EUR 0.51 Loans to customers and debt investments increased by 20.8% to EUR 638.1 million, impaired loan coverage ratio decreased to 16.6%Dividend proposal of EUR 0.19 per shareStrong confidence for outlook: 2024: EBIT guidance of EUR 67.5 million Mid-term 2026: net profit growth to EUR 30 million Helsinki, 28 March 2024 – Multitude SE, a listed European FinTech company, offering digital lending and online banking services to consumers, small and medium-sized businesses, and other FinTechs (ISIN: FI4000106299, WKN: A1W9NS) (“Multitude”, “Company” or “Group”) announces that the Group's Annual Report, Corporate Governance Statement and Remuneration Report for the financial year ended 31 December 2023 have been

NOTICE TO CONVENE MULTITUDE SE’S ANNUAL GENERAL MEETING OF SHAREHOLDERS28.3.2024 18:30:00 CET | Press release

NOTICE TO CONVENE MULTITUDE SE’S ANNUAL GENERAL MEETING OF SHAREHOLDERS Notice is given to the shareholders of Multitude SE (Company) that the Annual General Meeting of the Company is to be held on 25 April 2024 at 10:00 a.m. (EEST / Finnish time) at the offices of Castrén & Snellman Attorneys Ltd, Eteläesplanadi 14, Helsinki, Finland. The reception of persons who have registered for the meeting and the distribution of voting tickets will start at 9:30 a.m. (EEST / Finnish time). Shareholders may also exercise their voting rights by voting in advance. Instructions concerning advance voting are provided in Section 3.4 of this notice. It will not be possible to participate in the meeting or follow the meeting via an online stream or otherwise in real time by the use of telecommunication connections or technical means. The meeting will be held in the English language. 1 MATTERS ON THE AGENDA OF THE GENERAL MEETING OF SHAREHOLDERS At the General Meeting of Shareholders, the following matte

HiddenA line styled icon from Orion Icon Library.Eye